耐多药结核病合并糖尿病患者中的药物暴露与治疗结局:来自中国的多中心前瞻性队列研究
该多中心前瞻性队列纳入131例确诊耐多药结核病合并糖尿病患者,评估血糖控制对药物暴露的影响及药物暴露与治疗结局的关联。血糖控制不佳(糖化血红蛋白≥7%)与莫西沙星、利奈唑胺、贝达喹啉和环丝氨酸暴露降低独立相关,但与氯法齐明无关。药物暴露与药敏比值较高与良好治疗结局相关,贝达喹啉AUC/MIC≥245和莫西沙星AUC/MIC≥67可预测6个月培养转阴和良好结局。
要点
- 血糖控制不佳(糖化血红蛋白≥7%)与莫西沙星、利奈唑胺、贝达喹啉和环丝氨酸暴露降低独立相关,与氯法齐明无关。
- 药物暴露与药敏比值较高与良好耐多药结核病治疗结局相关。
- 贝达喹啉AUC/MIC≥245和莫西沙星AUC/MIC≥67可预测6个月培养转阴和良好结局。
核心结论
- 血糖控制与最佳结核药物暴露与改善的治疗结局相关,这一双重管理策略应在耐多药结核病合并糖尿病患者的随机对照试验中进一步验证。
研究设计与样本
- 多中心前瞻性队列研究,纳入131例确诊耐多药结核病合并糖尿病患者。
- 采用非房室分析估计药物暴露水平,并测定各结核分枝杆菌分离株的最低抑菌浓度(MIC)。
- 采用单因素和多因素分析评估血糖控制不佳(糖化血红蛋白≥7%)对药物暴露的影响及药物暴露与治疗结局的关联,并用分类与回归树分析确定药物暴露/药敏阈值。
主要发现
- 131例糖尿病患者中43例(32.8%)血糖控制不佳。
- 血糖控制不佳与莫西沙星、利奈唑胺、贝达喹啉和环丝氨酸暴露降低独立相关,但与氯法齐明无关。
- 较高的药物暴露与药敏比值与良好耐多药结核病治疗结局相关。
- 预测6个月培养转阴和良好结局的阈值为贝达喹啉AUC/MIC≥245和莫西沙星AUC/MIC≥67,无论血糖控制状态如何均显示预测准确性。
关键数值与推荐
- 血糖控制不佳定义为糖化血红蛋白≥7%。
- 预测6个月培养转阴和良好结局的阈值为贝达喹啉AUC/MIC≥245和莫西沙星AUC/MIC≥67。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of multidrug-resistant tuberculosis (MDR-TB) remains challenging. Treatment outcome is influenced by multiple factors; the specific roles of diabetes and glycemic control remain uncertain. This study aims to assess the impact of glycemic control on drug exposure, to investigate the association between drug exposure and treatment outcomes, and to identify clinically significant thresholds predictive of treatment outcome, among patients with diabetes. METHODS: This multicenter prospective cohort study involved patients with confirmed MDR-TB and diabetes. Drug exposure level was estimated by noncompartmental analysis. The minimum inhibitory concentrations (MICs) were determined for the individual Mycobacterium tuberculosis isolates. The influence of poor glycemic control (glycated hemoglobin ≥7%) on drug exposure and the associations between drug exposure and treatment outcome were evaluated by univariate and multivariate analysis. Classification and regression tree analysis was used to identify the drug exposure/susceptibility thresholds. RESULTS: Among the 131 diabetic participants, 43 (32.8%) exhibited poor glycemic control. Poor glycemic control was independently associated with decreased exposure to moxifloxacin, linezolid, bedaquiline, and cycloserine, but not clofazimine. Additionally, a higher ratio of drug exposure to susceptibility was found to be associated with a favorable MDR-TB treatment outcome. Thresholds predictive of 6-month culture conversion and favorable outcome were bedaquiline area under the concentration-time curve (AUC)/MIC ≥245 and moxifloxacin AUC/MIC ≥67, demonstrating predictive accuracy in patients, regardless of their glycemic control status. CONCLUSIONS: Glycemic control and optimal TB drug exposure are associated with improved treatment outcomes. This dual management strategy should be further validated in randomized controlled trials of patients with MDR-TB and diabetes.
引用
- Zhu Y, Forsman LD, Chen C, et al. Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China. Clin Infect Dis. 2024. PMID: 38913750. doi:10.1093/cid/ciae329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。